Results 31 to 40 of about 718,683 (284)

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

Journal for ImmunoTherapy of Cancer, 2021
Background Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions.
Dorota Wyczechowska, Amir A Al-Khami, Luis Del Valle, Augusto C Ochoa, Mohamed A Ghonim, Salome V Ibba, Abdelmetalab F Tarhuni, Youssef Errami, Hanh H Luu, Matthew J Dean, Ali H El-Bahrawy, Ilyes A Benslimane, A Hamid Boulares   +12 more
doaj   +1 more source

PARP-1 clusters

, 2023
List of genes in PARP-1 clusters in Drosophila third-instar larvae.
Gbolahan Bamgbose (15194764)
core   +2 more sources

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Journal of Experimental & Clinical Cancer Research, 2018
Background Targeting poly ADP-ribose polymerase (PARP) has been recently identified as a promising option against gastric cancer (GC). However, PARP inhibitors alone achieve limited efficacy.
Xiaoting Lin, Dongshao Chen, Cheng Zhang, Xiaotian Zhang, Zhongwu Li, Bin Dong, Jing Gao, Lin Shen   +7 more
doaj   +1 more source

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

Haematologica, 2009
Background Aberrant or impaired repair of double-strand DNA breaks is a common feature of de novo acute myeloid leukemia and myelodysplastic syndromes.
Terry J. Gaymes, Sydney Shall, Lee J. MacPherson, Natalie A. Twine, Nicholas C. Lea, Farzin Farzaneh, Ghulam J. Mufti   +6 more
doaj   +1 more source

WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment

Cancer Cell International, 2023
Background Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder defined by cytopenia and is associated with an increased risk of transformation to acute myeloid leukemia (AML).
Seiichi Okabe, Yuko Tanaka, Mitsuru Moriyama, Akihiko Gotoh   +3 more
doaj   +1 more source

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells [PDF]

, 2017
Mutations in homologous recombination (HR) genes BRCA1 and BRCA2 predispose to tumorigenesis. HR-deficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can acquire resistance and relapse. Mechanistic understanding how
Rottenberg, Sven, Gogola, Ewa, Bouwman, P, Gogola, E, Sohvi Blatter, van Vugt, Marcel A T M, van Vugt, MATM, van Vugt, Marcel A. T. M., Anne Margriet Heijink, Madalena Tarsounas, Foijer, Floris; id_orcid, Blatter, S, Foijer, Floris, Foijer, F, Peter Bouwman, Bouwman, Peter, Stok, Colin, Jos Jonkers, Schoonen, Pepijn M, Floris Foijer, Blatter, Sohvi, Talens, F, Jonkers, J, Schoonen, PM, Colin Stok, Marcel A. T. M. van Vugt, Heijink, Anne Margriet, Sven Rottenberg, Tarsounas, M, Pepijn M. Schoonen, van Vugt, Marcel A. T. M.; id_orcid, Jonkers, Jos, Francien Talens, Stok, C, Blatter, Sohvi Tuulikki, Tarsounas, Madalena, Schoonen, Pepijn M., Talens, Francien, Rottenberg, S, Heijink, AM, Ewa Gogola   +40 more
core   +4 more sources

Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells

EMBO Molecular Medicine, 2012
PARP inhibitors have been proposed as a potential targeted therapy for patients with triple‐negative (ER‐, PR‐, HER2‐negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be ...
Ilirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, Rachel Brough, Jessica Frankum, Christopher J. Lord, Alan Ashworth   +6 more
doaj   +1 more source

Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance

Gynecologic Oncology Reports
Objective: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy rechallenge is considered; however, its efficacy after poly adenosine 5 ...
Takehiro Nakao, Kenichi Harano, Masashi Wakabayashi, Yoichi Naito, Hiroshi Tanabe, Toru Mukohara   +5 more
doaj   +1 more source

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Journal of Experimental & Clinical Cancer Research, 2019
Background The muscle invasive form of urothelial bladder cancer (UBC) is a deadly disease. Currently, the therapeutic approach of UBC is mostly based on surgery and standard chemotherapy.
Francesco Morra, Francesco Merolla, Daniela Criscuolo, Luigi Insabato, Riccardo Giannella, Gennaro Ilardi, Aniello Cerrato, Roberta Visconti, Stefania Staibano, Angela Celetti   +9 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source